ulrich medical USA® Announces Strong Financial Performance of U.S. Spine Business

Delivers Record-Breaking 5-Year Results ~ 18% Revenue CAGR and 27% EBITDA CAGR

ST. LOUIS, MO (February 17, 2016) – ulrich medical USA Inc., a medical device company focused on developing and commercializing musculoskeletal implant technologies in the United States, today reported a fifth consecutive year of profitable, double-digit growth for the U.S. spine business and a 20% top line growth for the year ending December 31, 2015. Equally as strong, the company announced a 5-year revenue compound annual growth rate (CAGR) of 18% and a 27% EBITDA CAGR over the same period.

“We are extremely proud of our five-year performance and the accomplishments of our U.S. executive management team as it relates to the very successful development of a robust commercial enterprise,” said Christoph Ulrich, Managing Partner, ulrich medical®. “We are also very thankful to our customers who have tripled the use of our products and supported our ten new spinal implant product introductions in the United States during this same time period.”